Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Есть ли место короткодействующим бронхолитикам в современной терапии хронической обструктивной болезни легких?
Есть ли место короткодействующим бронхолитикам в современной терапии хронической обструктивной болезни легких?
Зыков К.А., Соколов Е.И. Есть ли место короткодействующим бронхолитикам в современной терапии хронической обструктивной болезни легких? Справочник поликлинического врача. 2016; 6: 22–26.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Хроническая обструктивная болезнь легких по прогнозам специалистов к 2020 г. выйдет на третье место в мире по смертности. В статье рассматриваются актуальные проблемы, связанные с особенностями диагностики и терапии этого заболевания. Особое внимание уделено применению комбинированного препарата в виде дозированного аэрозольного ингалятора (Беродуал Н) и раствора для небулайзера (Беродуал раствор), позволяющих применять Беродуал как по потребности при стабильном течении хронической обструктивной болезни легких, так и при обострении заболевания, выбирая форму доставки в зависимости от особенностей пациента и конкретной клинической ситуации.
Ключевые слова: хроническая обструктивная болезнь легких, лечение, ипратропий, фенотерол, Беродуал.
Key words: chronic obstructive pulmonary disease, medication, ipratropium, fenoterol, Berodual.
Ключевые слова: хроническая обструктивная болезнь легких, лечение, ипратропий, фенотерол, Беродуал.
________________________________________________
Key words: chronic obstructive pulmonary disease, medication, ipratropium, fenoterol, Berodual.
Полный текст
Список литературы
1. http://goldcopd.org/world-copd-day/
2. World Health Organization 2011. Reprinted 2011. WHO Library Cataloguing-in-Publication Data Global Status Report on Noncommunicable Diseases 2010. Geneva, 2011.
3. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
4. NMH/MND/CPM/13.1 Global alliance against chronic respiratory diseases (GARD) 7th General Meeting, 9–10 July 2012, St. Petersburg, Russia. http://www.who.int/gard/publications/GARDGMReportStPetersburg2012.pdf
5. Chuchalin A, Khaltaev N, Antonov N. Исследование хронических респираторных заболеваний и факторов риска в 12 регионах Российской Федерации. http://www.medlinks.ru/article.php?sid=61101 / Chuchalin A, Khaltaev N, Antonov N. Issledovanie khronicheskikh respiratornykh zabolevanii i faktorov riska v 12 regionakh Rossiiskoi Federatsii. http://www.medlinks.ru/article.php?sid=61101 [in Russian]
6. American Thoracic Society Foundation. The Global Burden of Lung Disease. 2014. http://foundation.thoracic.org/news/global-burden.php
7. Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Место фиксированной комбинации бронходилататоров длительного действия тиотропий/олодатерол в стартовой терапии хронической обструктивной болезни легких. Заключение совета экспертов Российского респираторного общества. Пульмонология. 2016; 24 (4): 505–13. / Avdeev S.N., Aisanov Z.R., Belevskii A.S. i dr. Mesto fiksirovannoi kombinatsii bronkhodilatatorov dlitel'nogo deistviia tiotropii/olodaterol v startovoi terapii khronicheskoi obstruktivnoi bolezni legkikh. Zakliuchenie soveta ekspertov Rossiiskogo respiratornogo obshchestva. Pul'monologiia. 2016; 24 (4): 505–13. [in Russian]
8. Salpeter SR. Cardiovascular safety of beta-adrenoreceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21 (6): 405–14.
9. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Российское респираторное общество. http://pulmonology.ru/download/COPD2014may2.doc / Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskoi obstruktivnoi bolezni legkikh. Rossiiskoe respiratornoe obshchestvo. http://pulmonology.ru/download/COPD2014may2.doc [in Russian]
10. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http://goldcopd.org.
11. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31 (4): 742–50.
12. Westby MJ. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; 3: CD003269.
13. Appleton S, Jones T, Poole P et al. Ipratropium bromid versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101.
14. Scuarcialupi MEA, Berton DC, Cordoni PK et al. Can bronchodilators improve exercise tolerance in COPD patients without dynamic hyperinflation? J Bras Pneumol 2014; 40 (2): 111–8.
15. Gani R, Griffin J, Kelly S, Rutten-vanMölken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010; 19 (1): 68–74.
16. Cole JM, Sheehan AH, Jordan JK. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Ann Pharmacother 2012; 46 (12): 1717–21.
17. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomized controlled trials. Respir Res 2007; 8: 19.
18. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novellong-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007; 29 (3): 575–81.
19. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2010. https://www.nice.org.uk/guidance/CG101
20. Celli BR, MacNee W, ATS ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
21. Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374 (9696): 1171–8.
22. Зыков К.А., Овчаренко С.И. Подходы к лекарственной терапии больных ХОБЛ стабильного течения: предлагаемый алгоритм лечения. Мед. совет. 2015; 17: 24–31. / Zykov K.A., Ovcharenko S.I. Podkhody k lekarstvennoi terapii bol'nykh KhOBL stabil'nogo techeniia: predlagaemyi algoritm lecheniia. Med. sovet. 2015; 17: 24–31. [in Russian]
23. Molimard M, Raherison C, Lignot S et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16 (3): 249–54.
24. Laube BL et al. What the pulmonary specialist should know about the new inhalation therapies. ERS/ISAM TASK FORCE REPORT. Eur Respir J 2011; 37: 1308–31.
25. Turner MO, Patel A, Ginsburg S, Fitzgerald JM. Bronchodilator delivery in acute air flow obstruction. A meta-analysis. Arch Intern Med 1997; 157 (15): 1736–44.
26. VandenBruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. MC Pulmonary Med 2010; 10: 50.
27. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 9: CD009552.
28. Bollu V, Ejzykowicz F, Rajagopalan K et al. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ 2013; 16 (8): 1082–8. DOI: 10.3111/13696998.2013.815625.
2. World Health Organization 2011. Reprinted 2011. WHO Library Cataloguing-in-Publication Data Global Status Report on Noncommunicable Diseases 2010. Geneva, 2011.
3. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
4. NMH/MND/CPM/13.1 Global alliance against chronic respiratory diseases (GARD) 7th General Meeting, 9–10 July 2012, St. Petersburg, Russia. http://www.who.int/gard/publications/GARDGMReportStPetersburg2012.pdf
5. Chuchalin A, Khaltaev N, Antonov N. Issledovanie khronicheskikh respiratornykh zabolevanii i faktorov riska v 12 regionakh Rossiiskoi Federatsii. http://www.medlinks.ru/article.php?sid=61101 [in Russian]
6. American Thoracic Society Foundation. The Global Burden of Lung Disease. 2014. http://foundation.thoracic.org/news/global-burden.php
7. Avdeev S.N., Aisanov Z.R., Belevskii A.S. i dr. Mesto fiksirovannoi kombinatsii bronkhodilatatorov dlitel'nogo deistviia tiotropii/olodaterol v startovoi terapii khronicheskoi obstruktivnoi bolezni legkikh. Zakliuchenie soveta ekspertov Rossiiskogo respiratornogo obshchestva. Pul'monologiia. 2016; 24 (4): 505–13. [in Russian]
8. Salpeter SR. Cardiovascular safety of beta-adrenoreceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21 (6): 405–14.
9. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskoi obstruktivnoi bolezni legkikh. Rossiiskoe respiratornoe obshchestvo. http://pulmonology.ru/download/COPD2014may2.doc [in Russian]
10. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http://goldcopd.org.
11. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31 (4): 742–50.
12. Westby MJ. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; 3: CD003269.
13. Appleton S, Jones T, Poole P et al. Ipratropium bromid versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101.
14. Scuarcialupi MEA, Berton DC, Cordoni PK et al. Can bronchodilators improve exercise tolerance in COPD patients without dynamic hyperinflation? J Bras Pneumol 2014; 40 (2): 111–8.
15. Gani R, Griffin J, Kelly S, Rutten-vanMölken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010; 19 (1): 68–74.
16. Cole JM, Sheehan AH, Jordan JK. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Ann Pharmacother 2012; 46 (12): 1717–21.
17. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomized controlled trials. Respir Res 2007; 8: 19.
18. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novellong-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007; 29 (3): 575–81.
19. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2010. https://www.nice.org.uk/guidance/CG101
20. Celli BR, MacNee W, ATS ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
21. Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374 (9696): 1171–8.
22. Zykov K.A., Ovcharenko S.I. Podkhody k lekarstvennoi terapii bol'nykh KhOBL stabil'nogo techeniia: predlagaemyi algoritm lecheniia. Med. sovet. 2015; 17: 24–31. [in Russian]
23. Molimard M, Raherison C, Lignot S et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16 (3): 249–54.
24. Laube BL et al. What the pulmonary specialist should know about the new inhalation therapies. ERS/ISAM TASK FORCE REPORT. Eur Respir J 2011; 37: 1308–31.
25. Turner MO, Patel A, Ginsburg S, Fitzgerald JM. Bronchodilator delivery in acute air flow obstruction. A meta-analysis. Arch Intern Med 1997; 157 (15): 1736–44.
26. VandenBruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. MC Pulmonary Med 2010; 10: 50.
27. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 9: CD009552.
28. Bollu V, Ejzykowicz F, Rajagopalan K et al. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ 2013; 16 (8): 1082–8. DOI: 10.3111/13696998.2013.815625.
2. World Health Organization 2011. Reprinted 2011. WHO Library Cataloguing-in-Publication Data Global Status Report on Noncommunicable Diseases 2010. Geneva, 2011.
3. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
4. NMH/MND/CPM/13.1 Global alliance against chronic respiratory diseases (GARD) 7th General Meeting, 9–10 July 2012, St. Petersburg, Russia. http://www.who.int/gard/publications/GARDGMReportStPetersburg2012.pdf
5. Chuchalin A, Khaltaev N, Antonov N. Исследование хронических респираторных заболеваний и факторов риска в 12 регионах Российской Федерации. http://www.medlinks.ru/article.php?sid=61101 / Chuchalin A, Khaltaev N, Antonov N. Issledovanie khronicheskikh respiratornykh zabolevanii i faktorov riska v 12 regionakh Rossiiskoi Federatsii. http://www.medlinks.ru/article.php?sid=61101 [in Russian]
6. American Thoracic Society Foundation. The Global Burden of Lung Disease. 2014. http://foundation.thoracic.org/news/global-burden.php
7. Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Место фиксированной комбинации бронходилататоров длительного действия тиотропий/олодатерол в стартовой терапии хронической обструктивной болезни легких. Заключение совета экспертов Российского респираторного общества. Пульмонология. 2016; 24 (4): 505–13. / Avdeev S.N., Aisanov Z.R., Belevskii A.S. i dr. Mesto fiksirovannoi kombinatsii bronkhodilatatorov dlitel'nogo deistviia tiotropii/olodaterol v startovoi terapii khronicheskoi obstruktivnoi bolezni legkikh. Zakliuchenie soveta ekspertov Rossiiskogo respiratornogo obshchestva. Pul'monologiia. 2016; 24 (4): 505–13. [in Russian]
8. Salpeter SR. Cardiovascular safety of beta-adrenoreceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21 (6): 405–14.
9. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Российское респираторное общество. http://pulmonology.ru/download/COPD2014may2.doc / Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskoi obstruktivnoi bolezni legkikh. Rossiiskoe respiratornoe obshchestvo. http://pulmonology.ru/download/COPD2014may2.doc [in Russian]
10. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http://goldcopd.org.
11. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31 (4): 742–50.
12. Westby MJ. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; 3: CD003269.
13. Appleton S, Jones T, Poole P et al. Ipratropium bromid versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101.
14. Scuarcialupi MEA, Berton DC, Cordoni PK et al. Can bronchodilators improve exercise tolerance in COPD patients without dynamic hyperinflation? J Bras Pneumol 2014; 40 (2): 111–8.
15. Gani R, Griffin J, Kelly S, Rutten-vanMölken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010; 19 (1): 68–74.
16. Cole JM, Sheehan AH, Jordan JK. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Ann Pharmacother 2012; 46 (12): 1717–21.
17. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomized controlled trials. Respir Res 2007; 8: 19.
18. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novellong-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007; 29 (3): 575–81.
19. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2010. https://www.nice.org.uk/guidance/CG101
20. Celli BR, MacNee W, ATS ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
21. Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374 (9696): 1171–8.
22. Зыков К.А., Овчаренко С.И. Подходы к лекарственной терапии больных ХОБЛ стабильного течения: предлагаемый алгоритм лечения. Мед. совет. 2015; 17: 24–31. / Zykov K.A., Ovcharenko S.I. Podkhody k lekarstvennoi terapii bol'nykh KhOBL stabil'nogo techeniia: predlagaemyi algoritm lecheniia. Med. sovet. 2015; 17: 24–31. [in Russian]
23. Molimard M, Raherison C, Lignot S et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16 (3): 249–54.
24. Laube BL et al. What the pulmonary specialist should know about the new inhalation therapies. ERS/ISAM TASK FORCE REPORT. Eur Respir J 2011; 37: 1308–31.
25. Turner MO, Patel A, Ginsburg S, Fitzgerald JM. Bronchodilator delivery in acute air flow obstruction. A meta-analysis. Arch Intern Med 1997; 157 (15): 1736–44.
26. VandenBruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. MC Pulmonary Med 2010; 10: 50.
27. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 9: CD009552.
28. Bollu V, Ejzykowicz F, Rajagopalan K et al. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ 2013; 16 (8): 1082–8. DOI: 10.3111/13696998.2013.815625.
________________________________________________
2. World Health Organization 2011. Reprinted 2011. WHO Library Cataloguing-in-Publication Data Global Status Report on Noncommunicable Diseases 2010. Geneva, 2011.
3. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.
4. NMH/MND/CPM/13.1 Global alliance against chronic respiratory diseases (GARD) 7th General Meeting, 9–10 July 2012, St. Petersburg, Russia. http://www.who.int/gard/publications/GARDGMReportStPetersburg2012.pdf
5. Chuchalin A, Khaltaev N, Antonov N. Issledovanie khronicheskikh respiratornykh zabolevanii i faktorov riska v 12 regionakh Rossiiskoi Federatsii. http://www.medlinks.ru/article.php?sid=61101 [in Russian]
6. American Thoracic Society Foundation. The Global Burden of Lung Disease. 2014. http://foundation.thoracic.org/news/global-burden.php
7. Avdeev S.N., Aisanov Z.R., Belevskii A.S. i dr. Mesto fiksirovannoi kombinatsii bronkhodilatatorov dlitel'nogo deistviia tiotropii/olodaterol v startovoi terapii khronicheskoi obstruktivnoi bolezni legkikh. Zakliuchenie soveta ekspertov Rossiiskogo respiratornogo obshchestva. Pul'monologiia. 2016; 24 (4): 505–13. [in Russian]
8. Salpeter SR. Cardiovascular safety of beta-adrenoreceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging 2004; 21 (6): 405–14.
9. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu khronicheskoi obstruktivnoi bolezni legkikh. Rossiiskoe respiratornoe obshchestvo. http://pulmonology.ru/download/COPD2014may2.doc [in Russian]
10. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http://goldcopd.org.
11. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31 (4): 742–50.
12. Westby MJ. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; 3: CD003269.
13. Appleton S, Jones T, Poole P et al. Ipratropium bromid versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101.
14. Scuarcialupi MEA, Berton DC, Cordoni PK et al. Can bronchodilators improve exercise tolerance in COPD patients without dynamic hyperinflation? J Bras Pneumol 2014; 40 (2): 111–8.
15. Gani R, Griffin J, Kelly S, Rutten-vanMölken M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010; 19 (1): 68–74.
16. Cole JM, Sheehan AH, Jordan JK. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Ann Pharmacother 2012; 46 (12): 1717–21.
17. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomized controlled trials. Respir Res 2007; 8: 19.
18. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novellong-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007; 29 (3): 575–81.
19. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2010. https://www.nice.org.uk/guidance/CG101
20. Celli BR, MacNee W, ATS ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46.
21. Decramer M, Celli B, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374 (9696): 1171–8.
22. Zykov K.A., Ovcharenko S.I. Podkhody k lekarstvennoi terapii bol'nykh KhOBL stabil'nogo techeniia: predlagaemyi algoritm lecheniia. Med. sovet. 2015; 17: 24–31. [in Russian]
23. Molimard M, Raherison C, Lignot S et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003; 16 (3): 249–54.
24. Laube BL et al. What the pulmonary specialist should know about the new inhalation therapies. ERS/ISAM TASK FORCE REPORT. Eur Respir J 2011; 37: 1308–31.
25. Turner MO, Patel A, Ginsburg S, Fitzgerald JM. Bronchodilator delivery in acute air flow obstruction. A meta-analysis. Arch Intern Med 1997; 157 (15): 1736–44.
26. VandenBruel A, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. MC Pulmonary Med 2010; 10: 50.
27. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 9: CD009552.
28. Bollu V, Ejzykowicz F, Rajagopalan K et al. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ 2013; 16 (8): 1082–8. DOI: 10.3111/13696998.2013.815625.
Авторы
К.А.Зыков*, Е.И.Соколов
ФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*kirillaz@inbox.ru
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*kirillaz@inbox.ru
ФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1
*kirillaz@inbox.ru
________________________________________________
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
*kirillaz@inbox.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.